Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma

Hematology/Oncology Clinics of North America

Volumn 26, Issue 3, 2012, Pages 671-704

  Zain, Jasmine ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Epigenetic therapy; Histone deacetylase inhibitors; Lymphoma; Multiple myeloma

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; BELINOSTAT; BORTEZOMIB; DACINOSTAT; DEPSIPEPTIDE; DEXAMETHASONE; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; LBH 586; LENALIDOMIDE; MOCETINOSTAT; NICOTINAMIDE; PANOBINOSTAT; ROMIDEPSIN; SIRTINOL; SK 7041; TACEDINALINE; TUBACIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

B CELL LYMPHOMA; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FATIGUE; FEVER; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MICROTUBULE ORGANIZING CENTER; MULTIPLE MYELOMA; MYELOMA; NAUSEA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; ST SEGMENT DEPRESSION; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTOPENIA; WEAKNESS;

HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LYMPHOMA; MULTIPLE MYELOMA;

EID: 84859955695     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.01.006     Document Type: Review

References (179)

1. Bhalla K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005, 23(17):3971-3993.
2. Bates S.E. Epigenetic therapies reach Main Street. Clin Cancer Res 2009, 15(12):3917.
3. Batty N., Malouf G.G., Issa J.P. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009, 280(2):192-200.
4. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-1159.
5. Hagelkruys A., Sawicka A., Rennmayr M., et al. The biology of HDAC in cancer: the nuclear and epigenetic components. Handb Exp Pharmacol 2011, 206:13-37.
6. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293(5532):1074-1080.
7. Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell 2004, 116(2):259-272.
8. Olsen E.A., Kim Y.H., Kuzel T.M., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25(21):3109-3115.
9. Demierre M. Pooled analysis of two international multicenter clinical studies of romidepsin in 167 patients with cutaneous lymphoma. 45th American Society of Clinical Oncology Annual Meeting, Atlanta, December 2009.
10. Piekarz R.L., Frye R., Prince H.M., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117(22):5827-5834.
11. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389(6649):349-352.
12. Davie J.R. Covalent modifications of histones: expression from chromatin templates. Curr Opin Genet Dev 1998, 8(2):173-178.
13. Zain J., Kaminetzky D., O'Connor O.A. Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. Expert Rev Hematol 2010, 3(2):187-203.
14. Marks P.A., Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005, 14(12):1497-1511.
15. Blander G., Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004, 73:417-435.
16. Zain J.M., O'Connor O. Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol 2010, 92(1):33-44.
17. Prince H.M., Bishton M., Harrison S. The potential of histone deacetylase inhibitors for the treatment of multiple myeloma. Leuk Lymphoma 2008, 49(3):385-387.
18. Piekarz R.L., Bates S.E. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009, 15(12):3918-3926.
19. O'Connor O.A., Heaney M.L., Schwartz L., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24(1):166-173.
20. Cotto M., Cabanillas F., Tirado M., et al. Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Clin Transl Oncol 2010, 12(6):401-409.
21. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5(1):37-50.
22. Nakagawa M., Oda Y., Eguchi T., et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007, 18(4):769-774.
23. Gloghini A., Buglio D., Khaskhely N.M., et al. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 2009, 147(4):515-525.
24. Haggarty S.J., Koeller K.M., Wong J.C., et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003, 100(8):4389-4394.
25. Simms-Waldrip T., Rodriguez-Gonzalez A., Lin T., et al. The aggresome pathway as a target for therapy in hematologic malignancies. Mol Genet Metab 2008, 94(3):283-286.
26. Wang J., Hoshino T., Redner R.L., et al. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A 1998, 95(18):10860-10865.
27. Lutterbach B., Westendorf J.J., Linggi B., et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 1998, 18(12):7176-7184.
28. Gelmetti V., Zhang J., Fanelli M., et al. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998, 18(12):7185-7191.
29. Lin R.J., Evans R.M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000, 5(5):821-830.
30. Minucci S., Maccarana M., Cioce M., et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 2000, 5(5):811-820.
31. Villagra A., Cheng F., Wang H.W., et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009, 10(1):92-100.
32. Villagra A., Sotomayor E.M., Seto E. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 2010, 29(2):157-173.
33. Marquard L., Gjerdrum L.M., Christensen I.J., et al. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008, 53(3):267-277.
34. van Doorn R., Gruis N.A., Willemze R., et al. Aberrant DNA methylation in cutaneous malignancies. Semin Oncol 2005, 32(5):479-487.
35. van Doorn R., Zoutman W.H., Dijkman R., et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005, 23(17):3886-3896.
36. Duvic M., Talpur R., Ni X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109(1):31-39.
37. Ellis L., Pan Y., Smyth G.K., et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008, 14(14):4500-4510.
38. Bates S.E., Zhan Z., Steadman K., et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010, 148(2):256-267.
39. Wozniak M.B., Villuendas R., Bischoff J.R., et al. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 2010, 95(4):613-621.
40. Weiss A., Littman D.R. Signal transduction by lymphocyte antigen receptors. Cell 1994, 76(2):263-274.
41. Dreyling M., Hoster E., Bea S., et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma (MCL): minutes of the 9th European MCL Network Conference. Leuk Lymphoma 2010, 51(9):1612-1622.
42. Prince H.M., Bishton M.J., Harrison S.J. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009, 15(12):3958-3969.
43. Pasqualucci L., Migliazza A., Basso K., et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003, 101(8):2914-2923.
44. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403(6769):503-511.
45. O'Connor O.A. Targeting histones and proteasomes: new strategies for the treatment of lymphoma. J Clin Oncol 2005, 23(26):6429-6436.
46. Lemercier C., Brocard M.P., Puvion-Dutilleul F., et al. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 2002, 277(24):22045-22052.
47. Ding B.B., Yu J.J., Yu R.Y., et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008, 111(3):1515-1523.
48. Skinnider B.F., Mak T.W. The role of cytokines in classical Hodgkin lymphoma. Blood 2002, 99(12):4283-4297.
49. Re D., Thomas R.K., Behringer K., et al. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005, 105(12):4553-4560.
50. Skinnider B.F., Kapp U., Mak T.W. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 2002, 43(6):1203-1210.
51. Kapp U., Yeh W.C., Patterson B., et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999, 189(12):1939-1946.
52. Yuan Z.L., Guan Y.J., Chatterjee D., et al. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307(5707):269-273.
53. Buglio D., Georgakis G.V., Hanabuchi S., et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008, 112(4):1424-1433.
54. Shichijo S., Yamada A., Sagawa K., et al. Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2'-deoxycytidine. Jpn J Cancer Res 1996, 87(7):751-756.
55. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004, 101(2):540-545.
56. Gray S.G., Qian C.N., Furge K., et al. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 2004, 24(4):773-795.
57. Neri P., Tagliaferri P., Di Martino M.T., et al. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 2008, 143(4):520-531.
58. Schwartz C., Palissot V., Aouali N., et al. Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. Int J Oncol 2007, 30(3):573-582.
59. Lavelle D., Westside Division, Chicago, et al. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 2001, 68(3):170-178.
60. Kaiser M., Zavrski I., Sterz J., et al. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006, 91(2):248-251.
61. Maiso P., Carvajal-Vergara X., Ocio E.M., et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006, 66(11):5781-5789.
62. Khan S.B., Maududi T., Barton K., et al. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 2004, 125(2):156-161.
63. Golay J., Cuppini L., Leoni F., et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007, 21(9):1892-1900.
64. Catley L., Weisberg E., Tai Y.T., et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003, 102(7):2615-2622.
65. Feng R., Ma H., Hassig C.A., et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol Cancer Ther 2008, 7(6):1494-1505.
66. Catley L., Weisberg E., Kiziltepe T., et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108(10):3441-3449.
67. Oancea M., Mani A., Hussein M.A., et al. Apoptosis of multiple myeloma. Int J Hematol 2004, 80(3):224-231.
68. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002, 2(6):420-430.
69. van de Donk N.W., Lokhorst H.M., Bloem A.C. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 2005, 19(12):2177-2185.
70. Gomez-Benito M., Martinez-Lorenzo M.J., Anel A., et al. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007, 313(11):2378-2388.
71. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003, 101(10):4055-4062.
72. Shao Y., Gao Z., Marks P.A., et al. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2004, 101(52):18030-18035.
73. Yamamoto S., Tanaka K., Sakimura R., et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res 2008, 28(3A):1585-1591.
74. Wickner S., Maurizi M.R., Gottesman S. Posttranslational quality control: folding, refolding, and degrading proteins. Science 1999, 286(5446):1888-1893.
75. Bennett E.J., Bence N.F., Jayakumar R., et al. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 2005, 17(3):351-365.
76. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000, 10(12):524-530.
77. Hideshima T., Bradner J.E., Wong J., et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005, 102(24):8567-8572.
78. Dong X.F., Song Q., Li L.Z., et al. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor. Neuro Endocrinol Lett 2007, 28(6):775-780.
79. Kitazoe K., Abe M., Hiasa M., et al. Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. Int J Hematol 2009, 89(1):45-57.
80. De Bruyne E., Bos T.J., Asosingh K., et al. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res 2008, 14(10):2918-2926.
81. Johnstone R.W., Licht J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell 2003, 4(1):13-18.
82. Kelly W.K., Richon V.M., O'Connor O., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9(10 Pt 1):3578-3588.
83. Sandor V., Bakke S., Robey R.W., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002, 8(3):718-728.
84. Garcia-Manero G., Assouline S., Cortes J., et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112(4):981-989.
85. Mann B.S., Johnson J.R., He K., et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007, 13(8):2318-2322.
86. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27(32):5459-5468.
87. Romidepsin (Istodax) for cutaneous T-cell lymphoma. Med Lett Drugs Ther 2010, 52(1339):42-43.
88. Matsuoka H., Unami A., Fujimura T., et al. Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol 2007, 571(2-3):88-96.
89. Bates S.E., Rosing D.R., Fojo T., et al. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res 2006, 12(13):3871-3874.
90. Strevel E.L., Ing D.J., Siu L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007, 25(22):3362-3371.
91. Piekarz R.L., Frye A.R., Wright J.J., et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006, 12(12):3762-3773.
92. Shah M.H., Binkley P., Chan K., et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006, 12(13):3997-4003.
93. Zain J., Rotter A., Weiss L., et al. Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma. Leuk Lymphoma 2007, 48(6):1216-1218.
94. Zhu Y.F., Ye B.G., Shen J.Z., et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010, 18(3):638-641. [in Chinese].
95. Watanabe T., Kato H., Kobayashi Y., et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 2010, 101(1):196-200.
96. Crump M., Coiffier B., Jacobsen E.D., et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008, 19(5):964-969.
97. Kirshbaum M., Zain J., Popplewell L., et al. Phase 2 study of suberoylanilide hydroxamic acid (SAHA) in relapsed or refractory indolent non-Hodgkin lymphoma: a California Cancer Consortium Study. J Clin Oncol 2007, 25(18S). [abstract: 18515].
98. Gimsing P., Hansen M., Knudsen L.M., et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008, 81(3):170-176.
99. Steele N.L., Plumb J.A., Vidal L., et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor belinostat (PXD101). Cancer Chemother Pharmacol 2011, 67(6):1273-1279.
100. Zain J. Preliminary results of an ongoing phase I trial of oral belinostat a novel histone deacetylase inhibitor in patients with lymphoid malignancies. Blood 2011, (ASH abstract book 3710).
101. Evans A. Phase 1 analysis of the safety and pharmacodynamics of the novel broad spectrum HDACi PCI-24781 in relapsed and refractory lymphoma. Blood 2009, 114. [abstract: 2726].
102. Jaffe E.S., Harris N.L., Stein H., et al. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008, 112(12):4384-4399.
103. Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105(10):3768-3785.
104. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26(25):4124-4130.
105. Piekarz R.L., Frye R., Turner M., et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009, 27(32):5410-5417.
106. Coiffier B. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-Cell lymphoma (PTCL) following prior systemic therapy. Blood 2010, 114:116. (ASH abstract book).
107. Pohlman B. Final results of a phase 2 trial of belinostat in patients with recurrent or refractory peripheral or cutaneous T cell lymphomas. Blood 2009, [abstract: 920].
108. Stevens S.R., Ke M.S., Parry E.J., et al. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol 2002, 138(1):42-48.
109. Konstantinopoulos P.A., Vandoros G.P., Papavassiliou A.G. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother Pharmacol 2006, 58(5):711-715.
110. Piekarz R.L., Robey R., Sandor V., et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001, 98(9):2865-2868.
111. Whittaker S.J., Demierre M.F., Kim E.J., et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010, 28(29):4485-4491.
112. Olsen E., Duvic M., Frankel A., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001, 19(2):376-388.
113. Ali C.M., Sikdar T.K., Sultana N., et al. Sezary syndrome. Mymensingh Med J 2011, 20(3):497-500.
114. Steele N.L., Plumb J.A., Vidal L., et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008, 14(3):804-810.
115. Duvic M. Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T cell lymphoma (CTCL). J Clin Oncol 2008, 26(Suppl). [abstract: 8555].
116. Thompson C.A., Mauck K., Havyer R., et al. Care of the adult Hodgkin lymphoma survivor. Am J Med 2011, 124(12):1106-1112.
117. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
118. Kewalramani T., Nimer S.D., Zelenetz A.D., et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003, 32(7):673-679.
119. Kirshbaum M. Vorinostat in relapsed or refractory Hodgkin lymphoma: SWOG 0517. Blood 2007, 110. [abstract: 2574].
120. Sureda A. Final analysis: phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma in patients following autologous stem cell transplant. Blood 2010, 116. [abstract: 419], (ASH abstract book) 2010.
121. Younes A. Isotype-selective HDAC-inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical HL. Blood 2007, 110. [abstract: 2566].
122. Richardson P., Mitsiades C., Colson K., et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008, 49(3):502-507.
123. Niesvizky R., Ely S., Mark T., et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011, 117(2):336-342.
124. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003, 29(Suppl 1):3-9.
125. Kikuchi J., Wada T., Shimizu R., et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010, 116(3):406-417.
126. Pei X.Y., Dai Y., Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004, 10(11):3839-3852.
127. Feng R., Oton A., Mapara M.Y., et al. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007, 139(3):385-397.
128. Nawrocki S.T., Carew J.S., Maclean K.H., et al. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008, 112(7):2917-2926.
129. Siegel D.S., Jagannath S., Hajek R., et al. Vorinostat combined with bortezomib in patients with relapsed or relapsed and refractory multiple myeloma: update on the Vantage Study Program. Blood 2010, 116(21). (ASH meeting abstract # 1952).
130. Mazumder A., Vesole D.H., Jagannath S. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. Clin Lymphoma Myeloma Leuk 2010, 10(2):149-151.
131. Jagannath S., Dimopoulos M.A., Lonial S. Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed/refractory multiple myeloma. Leuk Res 2010, 34(9):1111-1118.
132. Kiziltepe T., Hideshima T., Catley L., et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 2007, 6(6):1718-1727.
133. Ocio E.M., Mateos M.V., Maiso P., et al. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008, 9(12):1157-1165.
134. Zhu W.G., Otterson G.A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 2003, 3(3):187-199.
135. De Bruyne E. Regulation of Bim expression by IGF-1 in the 5T33MM murine model for multiple myeloma. Blood 2007, 110:3512. (ASH abstract book).
136. Catley L., Tai Y.T., Chauhan D., et al. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist Updat 2005, 8(4):205-218.
137. Fandy T.E., Shankar S., Ross D.D., et al. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005, 7(7):646-657.
138. Shankar S., Singh T.R., Fandy T.E., et al. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 2005, 16(6):1125-1138.
139. Paoluzzi L., Scotto L., Marchi E., et al. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 2010, 16(2):554-565.
140. Heider U., von Metzler I., Kaiser M., et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008, 80(2):133-142.
141. Dai Y., Chen S., Kramer L.B., et al. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res 2008, 14(2):549-558.
142. Dasmahapatra G., Lembersky D., Kramer L., et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010, 115(22):4478-4487.
143. Luo J., Nikolaev A.Y., Imai S., et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107(2):137-148.
144. Amengual J. DNA methylation is involved in malignancy and is seen, in progression, in more than 80% of all solid tumours. Methylation is one of the main physiological processes to induce silencing of gene expression. Blood 2011, (ASH meeting abstract # 3733).
145. Dummer R. Phase I trial of oral vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma. Haematologica 2008, 93(sl):110. [abstract 0270].
146. Marchi E. Combination of epigenetic agents synergistically reverse the malignant phenotype in models of T-cell lymphoma. Blood 2011, (ASH meeting abstract # 2727).
147. Gregoretti I.V., Lee Y.M., Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004, 338(1):17-31.
148. Hubbert C., Guardiola A., Shao R., et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417(6887):455-458.
149. Gao L., Cueto M.A., Asselbergs F., et al. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002, 277(28):25748-25755.
150. Kramer O.H., Zhu P., Ostendorff H.P., et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003, 22(13):3411-3420.
151. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5(9):769-784.
152. Hu E., Dul E., Sung C.M., et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003, 307(2):720-728.
153. Furumai R., Matsuyama A., Kobashi N., et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002, 62(17):4916-4921.
154. Guo F., Sigua C., Tao J., et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004, 64(7):2580-2589.
155. Nebbioso A., Clarke N., Voltz E., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005, 11(1):77-84.
156. Nagata S., Golstein P. The Fas death factor. Science 1995, 267(5203):1449-1456.
157. Newbold A., Lindemann R.K., Cluse L.A., et al. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 2008, 7(5):1066-1079.
158. Lindemann R.K., Newbold A., Whitecross K.F., et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A 2007, 104(19):8071-8076.
159. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science 1998, 281(5381):1312-1316.
160. Hofmann K. The modular nature of apoptotic signaling proteins. Cell Mol Life Sci 1999, 55(8-9):1113-1128.
161. Peart M.J., Tainton K.M., Ruefli A.A., et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003, 63(15):4460-4471.
162. Kim M.S., Kwon H.J., Lee Y.M., et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001, 7(4):437-443.
163. Jeong J.W., Bae M.K., Ahn M.Y., et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002, 111(5):709-720.
164. Duvic M., Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007, 16(7):1111-1120.
165. Peart M.J., Smyth G.K., van Laar R.K., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005, 102(10):3697-3702.
166. Zhao Y., Lu S., Wu L., et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 2006, 26(7):2782-2790.
167. Dai Y., Rahmani M., Dent P., et al. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005, 25(13):5429-5444.
168. Spange S., Wagner T., Heinzel T., et al. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009, 41(1):185-198.
169. Bereshchenko O.R., Gu W., Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002, 32(4):606-613.
170. Dai Y., Chen S., Wang L., et al. Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors. J Biol Chem 2011, 286(39):34036-34050.
171. Munshi A., Kurland J.F., Nishikawa T., et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005, 11(13):4912-4922.
172. Cohen H.Y., Lavu S., Bitterman K.J., et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004, 13(5):627-638.
173. Kovacs J.J., Murphy P.J., Gaillard S., et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005, 18(5):601-607.
174. Wang Y., Wang S.Y., Zhang X.H., et al. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem Biophys Res Commun 2007, 356(4):998-1003.
175. Robbins A.R., Jablonski S.A., Yen T.J., et al. Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 2005, 4(5):717-726.
176. Ruefli A.A., Ausserlechner M.J., Bernhard D., et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001, 98(19):10833-10838.
177. Butler L.M., Zhou X., Xu W.S., et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 2002, 99(18):11700-11705.
178. Weiser T.S., Ohnmacht G.A., Guo Z.S., et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 2001, 71(1):295-301. [discussion: 301-2].
179. Weiser T.S., Guo Z.S., Ohnmacht G.A., et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 2001, 24(2):151-161.